Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis.
Elliott
M A
MA
Pardanani
A
A
Li
C Y
CY
Tefferi
A
A
D000328:Adult; D001549:Benzamides; D001854:Bone Marrow Cells / Q000276:immunology / Q000473:pathology; D004802:Eosinophilia / Q000150:complications* / Q000276:immunology / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D016130:Immunophenotyping; D008297:Male; D008407:Mast Cells / Q000276:immunology* / Q000473:pathology; D034721:Mastocytosis, Systemic / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate